Advanced Solid TumorsPhase 1NCT06384352
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
A Phase 1 study testing YL211, YL211+Pembrolizumab and YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin) in people with Advanced Solid Tumors, run by MediLink Therapeutics (Suzhou) Co., Ltd. at 21 sites in 4 countries.
Trial summary
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tumors (Part 1) and in… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Solid Tumors
- What is being tested?
- YL211, YL211+Pembrolizumab and YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 21 sitesin 4 countries
- Study dates
- 1 May 2024to 30 Jun 2031
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Informed of the trial before the start of the trial and voluntarily sign their name and date on the ICF.
- Aged ≥18 years.
- Be able and willing to comply with protocol visits and procedures.
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or
- Adequate organ and bone marrow function.
- For Part 1: History of an advanced solid tumors (including locally advanced unresectable or metastatic NSCLC, metastatic colorectal carcinoma (mCRC), advanced gastric adenocarcinoma (GAC)/ gastroesophageal junction adenocarcinoma (GEJA), pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), intrahepatic biliary tract cancer (ih-BTC), and head and neck squamous cell carcinoma (HNSCC) who failed currently available standard therapies and are not amenable to surgical resection, or for whom no available standard therapy or no other approved therapeutic options that have demonstrated clinical benefit.
Show all 10Show fewer
- For Part 2: For patients with CRC: History of histologically or cytologically confirmed diagnosis of metastatic CRC and at least 2 prior regimens of standard treatment For patients with NSCLC: History of histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic NSCLC and no more than 2 lines of prior cytotoxic systemic therapy in the locally advanced or metastatic setting.
- For Part 3: History of histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic non-squamous (Part 3A) or squamous (Part 3B) NSCLC and no more than 2 lines of prior systemic therapy
- For Part 4: History of histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic non-squamous NSCLC who have progressed on or after 1 or 2 prior lines of systemic therapy
- For Part 5 and Part 6 Histologically or cytologically documented locally advanced unresectable or metastatic non-squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy and no prior systemic treatment for advanced unresectable or metastatic NSCLC
Who cannot join
- Prior treatment with an agent targeting c-MET (including antibody, ADC, chimeric antigen receptor T cell [CAR-T], and other drugs) with the exception of prior treatment with MET-targeted TKIs which are allowed.
- Previously received an ADC consisting of a TopoI
- Received continuous systemic steroids therapy for more than 28 days or require long-term (≥ 28 days) use of systemic steroids therapy within 28 days before the first administration, or have other acquired or congenital immune deficiency diseases. (Note: The protocol lists specific situational exceptions immediately following this clause).
- A history of leptomeningeal carcinomatosis or carcinomatous meningitis
- Brain metastasis, except for the following situations:
- Participants with asymptomatic brain metastasis who do not require immediate local or systemic treatment (such as mannitol or steroids, surgery, or radiotherapy) are allowed to be enrolled If the participant's brain metastasis is treated and the condition of the metastasis is stable (brain imaging examination at least 2 weeks before the first administration shows that the lesion is stable, there is no evidence of new or original brain metastasis enlargement, there are no new neurological symptoms, and immediate local or systemic treatment is not required), admission is allowed
- Clinically significant concomitant pulmonary disease, including but not limited to:
- A history of drug-induced pneumonitis A history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that requires steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
Trial locations and contacts
21 sites in 4 countries. Contact the study team or a site near you to ask about taking part.
21 sites in 4 countries
United States11 sites, 11 recruiting
- Recruiting
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado, 80045
Ashley Fisher, ASHLEY.R.FISHER@CUANSCHUTZ.EDU
Antonio Jimeno
- Recruiting
University of Cincinnati Vontz Center for Molecular Studies
Cincinnati, Ohio, 45219
site coordinator
- Recruiting
Sarah Cannon Research Institute (SCRI) at HealthONE
Denver, Colorado, 80218-1238
Jason Henry, Jason.Henry2@sarahcannon.com
Jason Henry
- Recruiting
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030
Coordinator Clinical operation director, RA@medilinkthera.com
- Recruiting
NEXT Oncology - Houston
Houston, Texas, 77055
site coordinator
- Recruiting
NEXT Oncology - Dallas
Irving, Texas, 75039
Erica Torres, etorres@nextoncology.com
Shiraj Sen
- Recruiting
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
Las Vegas, Nevada, 89169
site coordinator
- Recruiting
Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven
North Haven, Connecticut, 06473-2142
Anastasio Gabrielle, gabrielle.anastasio@yale.edu
Michael Cecchini
- Recruiting
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827
Elizabeth Gilmore, Elizabeth.Griffith@scri.com
Cesar Perez
- Recruiting
NEXT San Antonio
San Antonio, Texas, 78229
Coordinator Clinical operation director, RA@medilinkthera.com
- Recruiting
Florida Cancer Specialists & Research Institute (FCS) - Sarasota Cattlemen Office
Sarasota, Florida, 34232-6422
Carly Taylor, ctaylor@flcancer.com
Manish Patel
China5 sites, 5 recruiting
- Recruiting
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029
site coordinator
- Recruiting
West China Hospital, Sichuan University
Chengdu
Yan Zhang, 18980601166@qq.com
Yan Zhang
- Recruiting
Sun Yat-sen University Cancer Center
Guangzhou
Danyun Ruan, ruandy1@sysucc.org.cn
Ruihua Xu
- Recruiting
The First Affiliated Hospital - Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003
site coordinator
- Recruiting
Wenzhou Medical University - The First Affiliated Hospital
Wenzhou, Zhejiang, 325000
site coordinator
Australia3 sites, 3 recruiting
- Recruiting
Gosford Hospital
Gosford, New South Wales, 2250
site coordinator
- Recruiting
Monash Health
Melbourne
Sophia Frentzas, sophia.frentzas@monash.edu
Sophia Frentzas
- Recruiting
One Clinical Research - Nedlands
Nedlands, Western Australia, 6009
site coordinator
Canada2 sites, 2 recruiting
- Recruiting
The Ottawa Hospital - General Campus
Ottawa
Jura Nakamura, junakamura@ohri.ca
Scott Laurie
- Recruiting
Princess Margaret Hospital
Toronto, Toronto
Albiruni Razak, Albiruni.razak@uhn.ca
Albiruni Razak
About this study
Official title: A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tumors (Part 1) and in combination with pembrolizumab in patients with second or third line locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) (Part 4) To determine the maximum tolerated dose (MTD) and select the recommended expansion dose(s) (RED(s)) of YL211 as monotherapy in patients with advanced solid tumors (Part 1) and in combination with pembrolizumab in patients with second line locally advanced unresectable or metastatic non-squamous NSCLC (Part 4) Objectives for Backfill Enrollment Parts (Part 2 and Part 5) To better estimate and characterize the safety and efficacy of YL211 as monotherapy in patients with metastatic colorectal cancer (mCRC) or locally advanced unresectable or metastatic NSCLC (Part 2) and in combination with pembrolizumab in patients with previously untreated locally advanced unresectable or metastatic non-squamous NSCLC (Part 5) To select the RED(s) of YL211 as monotherapy in patients with metastatic colorectal cancer (mCRC) or locally advanced unresectable or metastatic NSCLC (Part 2) and in combination with pembrolizumab in patients with previously untreated locally advanced unresectable or metastatic non-squamous NSCLC (Part 5) Objectives for the Dose-Expansion Parts (Part 3 and Part 6) To further characterize the safety and efficacy of YL211 as monotherapy (Part 3) in patients with locally advanced unresectable or metastatic non-squamous or squamous NSCLC and in combination with pembrolizumab in patients with previously untreated locally advanced unresectable or metastatic non- squamous NSCLC (Part 6) To compare the clinical activity of YL211 in combination with pembrolizumab against pembrolizumab, pemetrexed, and platinum-based chemotherapy (cisplatin or carboplatin) in participants with previously untreated advanced unresectable or metastatic non-squamous NSCLC (Part 6)
- Conditions
- Advanced Solid Tumors
- Being tested
- YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
YL211Drug
Patients will be treated with YL211 intravenous (IV) infusion only.
YL211+PembrolizumabDrug
Patients will be treated with YL211 and Pembro by infusion.
YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)Drug
participants will receive therapy YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin) by infusion.(Part 6)
| Study group | Role | What they receive |
|---|---|---|
| Part 1 | Experimental | YL211 Monotherapy Dose Esclation Receives: Drug: YL211 |
| Part 2 | Experimental | YL211 Monotherapy Backfill Receives: Drug: YL211 |
| Part 3 | Experimental | YL211 Monotherapy Dose Expansion Receives: Drug: YL211 |
| Part 4 | Experimental | YL211 + Pembro Combination Therapy Dose Esclation Receives: Drug: YL211+Pembrolizumab |
| Part 5 | Experimental | YL211 + Pembro Combination Therapy Backfill Receives: Drug: YL211+Pembrolizumab |
| Part 6 | Active comparator | YL211 + Pembro Combination Therapy or Pembro + Chemo Combination Therapy Dose Expansion Receives: Drug: YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Nature and frequency of adverse events (AEs) with severity determined according to NCI CTCAE v5.0 (Part 1 and Part 4)
AE's
Measured: Approximately within 36 months
Nature and frequency of dose-limiting toxicities (DLTs) (Part 1 and Part 4)
DLTs
Measured: Approximately within 36 months
Nature and frequency of AEs with severity, physical examination findings (including ECOG PS), vital sign measurements, standard clinical laboratory parameters, SpO2 measurements, ECG parameters, and ECHO findings (Part 2 and Part 5)
Safety
Measured: Approximately within 36 months
ORR assessed using RECIST version 1.1 (Part 2 and Part 5)
Efficacy
Measured: Approximately within 36 months
PFS using RECIST version 1.1 defined as the time interval of randomization to the date of first documentation of PD or death due to any cause, whichever occurs first (Part 3 and Part 6)
Efficacy
Measured: approximately 36 months
Nature and frequency of AEs with severity, physical examination findings (including ECOG PS), vital sign measurements, standard clinical laboratory parameters, SpO2 measurements, ECG parameters, and ECHO findings (Part 3 and Part 6)
Safety
Measured: approximately within 36 months
Secondary outcomes (12)
physical examination findings (including Eastern Cooperative Oncology Group performance status; ECOG PS), vital sign measurements, standard clinical laboratory parameters, SpO2 measurements, ECG parameters, and ECHO findings (Part 1 and Part 4)
other safety endpoints
Measured: Approximately within 36 months
PK enpoints (Part 1 and Part 4)
Pharmacokinetic endpoints: for each participant will be estimated using standard non-compartmental methods. Descriptive statistics will be provided for all serum concentration data and PK parameter values, with a break down by dose level/cohort as appropriate. PK parameters of YL211-ADC, YL211-TAb, unconjugated payload YL0010014, metabolite YL0010034 and if applicable, other potential metabolite(s), include but not limited to area under the curve (AUC), maximum concentration (Cmax), trough concentration (Ctrough), time of maximum observed concentration (Tmax), clearance (CL), volume of distribution (Vd), and half-life time (t1/2)
Measured: Approximately within 36 months
Incidence of anti-YL211 antibody (ADA) (Part 1 and Part 4)
ADA
Measured: Approximately within 36 months
Efficacy endpoints (Part 1 and Part 4)
Tumor response will be evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Efficacy variables include objective response rate (ORR, the sum of complete response [CR] rate and partial response [PR] rate), disease control rate (DCR, the sum of CR rate, PR rate, and stable disease [SD] rate), duration of response (DoR), duration of SD, time to response (TTR), and progression free survival (PFS), overall survival (OS), percent change in target lesion, time on therapy of the most recent prior regimen the participant received and that of YL211. The efficacy variable(s) will be also evaluated at 18 weeks after Day 1 of Cycle 1.
Measured: approximately 36 months
PK parameters of YL211-ADC, YL211-TAb, unconjugated payload YL0010014, and if applicable, potential metabolite(s), including but not limited to AUC, Cmax, Ctrough, Tmax, CL, Vd, and t1/2 (Part 2 and Part 5)
PK
Measured: approximately 36 months
DCR, DoR, TTR, PFS, OS, and best tumor response assessed using RECIST version 1.1 (Part 2 and Part 5)
Measured: approximately 36mo
Incidence of ADA (Part 2 and Part 5)
Measured: approximately 36mo
c-MET protein expression level in tumor tissues and its relationship with efficacy endpoints (Part 5)
Measured: approximately 36mo
Plasma or serum concentration of YL211-ADC, YL211-TAb, unconjugated payload YL0010014, and if applicable, potential metabolite(s), at specified time points (Part 3 and Part 6)
Measured: approximately 36mo
Incidence of ADA (Part 3 and Part 6)
Measured: approximately 36mo
ORR, DCR, DoR, TTR, OS, and best tumor response assessed using RECIST version 1.1 (Part 3 and Part 6)
Measured: approximately 36mo
c-MET protein expression level in tumor tissues and its relationship with efficacy endpoints (Part 3 and Part 6)
Measured: Approximately 36mo
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Apr 2024
- Study start1 May 2024
- Primary completion30 Jun 2031 (estimated)
- Study completion30 Jun 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Solid TumorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Sequential: (Dose escalation Parts 1 and 4) Parallel Backfill (Parts 2 and 5) Dose expansion(Parts 3 and 6)
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Hoffmann-La Roche
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06384352
- Sponsor's protocol ID
- YL211-INT-101-01
- Status last verified
- Aug 2026
- First submitted
- 26 Mar 2024
- Last updated
- 13 Aug 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
- ClinicalTrials.gov ID
- NCT06384352
- Acronym / sponsor ID
- YL211-INT-101-01
- Conditions
- Advanced Solid Tumors
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.Industry (pharma, biotech, devices)
- Collaborators
- Hoffmann-La Roche
- Study start
- 1 May 2024 (actual)
- Primary completion
- 30 Jun 2031 (estimated)
- Study completion
- 30 Jun 2031 (estimated)
- First posted
- 25 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tumors (Part 1) and in combination with pembrolizumab in patients with second or third line locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) (Part 4) To determine the maximum tolerated dose (MTD) and select the recommended expansion dose(s) (RED(s)) of YL211 as monotherapy in patients with advanced solid tumors (Part 1) and in combination with pembrolizumab in patients with second line locally advanced unresectable or metastatic non-squamous NSCLC (Part 4) Objectives for Backfill Enrollment Parts (Part 2 and Part 5) To better estimate and characterize the safety and efficacy of YL211 as monotherapy in patients with metastatic colorectal cancer (mCRC) or locally advanced unresectable or metastatic NSCLC (Part 2) and in combination with pembrolizumab in patients with previously untreated locally advanced unresectable or metastatic non-squamous NSCLC (Part 5) To select the RED(s) of YL211 as monotherapy in patients with metastatic colorectal cancer (mCRC) or locally advanced unresectable or metastatic NSCLC (Part 2) and in combination with pembrolizumab in patients with previously untreated locally advanced unresectable or metastatic non-squamous NSCLC (Part 5) Objectives for the Dose-Expansion Parts (Part 3 and Part 6) To further characterize the safety and efficacy of YL211 as monotherapy (Part 3) in patients with locally advanced unresectable or metastatic non-squamous or squamous NSCLC and in combination with pembrolizumab in patients with previously untreated locally advanced unresectable or metastatic non- squamous NSCLC (Part 6) To compare the clinical activity of YL211 in combination with pembrolizumab against pembrolizumab, pemetrexed, and platinum-based chemotherapy (cisplatin or carboplatin) in participants with previously untreated advanced unresectable or metastatic non-squamous NSCLC (Part 6)
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 6
- Model description
- Sequential: (Dose escalation Parts 1 and 4) Parallel Backfill (Parts 2 and 5) Dose expansion(Parts 3 and 6)
| Arm | Type | Receives |
|---|---|---|
| Part 1 | Experimental | Drug: YL211YL211 Monotherapy Dose Esclation |
| Part 2 | Experimental | Drug: YL211YL211 Monotherapy Backfill |
| Part 3 | Experimental | Drug: YL211YL211 Monotherapy Dose Expansion |
| Part 4 | Experimental | Drug: YL211+PembrolizumabYL211 + Pembro Combination Therapy Dose Esclation |
| Part 5 | Experimental | Drug: YL211+PembrolizumabYL211 + Pembro Combination Therapy Backfill |
| Part 6 | Active comparator | Drug: YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)YL211 + Pembro Combination Therapy or Pembro + Chemo Combination Therapy Dose Expansion |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Informed of the trial before the start of the trial and voluntarily sign their name and date on the ICF.
- Aged ≥18 years.
- Be able and willing to comply with protocol visits and procedures.
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or
- Adequate organ and bone marrow function.
Key exclusion criteria (8 listed)
- Prior treatment with an agent targeting c-MET (including antibody, ADC, chimeric antigen receptor T cell [CAR-T], and other drugs) with the exception of prior treatment with MET-targeted TKIs which are allowed.
- Previously received an ADC consisting of a TopoI
- Received continuous systemic steroids therapy for more than 28 days or require long-term (≥ 28 days) use of systemic steroids therapy within 28 days before the first administration, or have other acquired or congenital immune deficiency diseases. (Note: The protocol lists specific situational exceptions immediately following this clause).
- A history of leptomeningeal carcinomatosis or carcinomatous meningitis
- Brain metastasis, except for the following situations:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| YL211Patients will be treated with YL211 intravenous (IV) infusion only. | Drug | Part 1, Part 2, Part 3 |
| YL211+PembrolizumabPatients will be treated with YL211 and Pembro by infusion. | Drug | Part 4, Part 5 |
| YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)participants will receive therapy YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin) by infusion.(Part 6) | Drug | Part 6 |
Primary outcome
Nature and frequency of adverse events (AEs) with severity determined according to NCI CTCAE v5.0 (Part 1 and Part 4)
Time frame: Approximately within 36 months
AE's
Nature and frequency of dose-limiting toxicities (DLTs) (Part 1 and Part 4)
Time frame: Approximately within 36 months
DLTs
Nature and frequency of AEs with severity, physical examination findings (including ECOG PS), vital sign measurements, standard clinical laboratory parameters, SpO2 measurements, ECG parameters, and ECHO findings (Part 2 and Part 5)
Time frame: Approximately within 36 months
Safety
ORR assessed using RECIST version 1.1 (Part 2 and Part 5)
Time frame: Approximately within 36 months
Efficacy
PFS using RECIST version 1.1 defined as the time interval of randomization to the date of first documentation of PD or death due to any cause, whichever occurs first (Part 3 and Part 6)
Time frame: approximately 36 months
Efficacy
Nature and frequency of AEs with severity, physical examination findings (including ECOG PS), vital sign measurements, standard clinical laboratory parameters, SpO2 measurements, ECG parameters, and ECHO findings (Part 3 and Part 6)
Time frame: approximately within 36 months
Safety
12 secondary outcomes
physical examination findings (including Eastern Cooperative Oncology Group performance status; ECOG PS), vital sign measurements, standard clinical laboratory parameters, SpO2 measurements, ECG parameters, and ECHO findings (Part 1 and Part 4)
Time frame: Approximately within 36 months
PK enpoints (Part 1 and Part 4)
Time frame: Approximately within 36 months
Incidence of anti-YL211 antibody (ADA) (Part 1 and Part 4)
Time frame: Approximately within 36 months
Efficacy endpoints (Part 1 and Part 4)
Time frame: approximately 36 months
PK parameters of YL211-ADC, YL211-TAb, unconjugated payload YL0010014, and if applicable, potential metabolite(s), including but not limited to AUC, Cmax, Ctrough, Tmax, CL, Vd, and t1/2 (Part 2 and Part 5)
Time frame: approximately 36 months
DCR, DoR, TTR, PFS, OS, and best tumor response assessed using RECIST version 1.1 (Part 2 and Part 5)
Time frame: approximately 36mo
Incidence of ADA (Part 2 and Part 5)
Time frame: approximately 36mo
c-MET protein expression level in tumor tissues and its relationship with efficacy endpoints (Part 5)
Time frame: approximately 36mo
Plasma or serum concentration of YL211-ADC, YL211-TAb, unconjugated payload YL0010014, and if applicable, potential metabolite(s), at specified time points (Part 3 and Part 6)
Time frame: approximately 36mo
Incidence of ADA (Part 3 and Part 6)
Time frame: approximately 36mo
ORR, DCR, DoR, TTR, OS, and best tumor response assessed using RECIST version 1.1 (Part 3 and Part 6)
Time frame: approximately 36mo
c-MET protein expression level in tumor tissues and its relationship with efficacy endpoints (Part 3 and Part 6)
Time frame: Approximately 36mo
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
Related trials for Advanced Solid Tumors
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
21 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing YL211, YL211+Pembrolizumab and YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin) in people with Advanced Solid Tumors, run by MediLink Therapeutics (Suzhou) Co., Ltd. at 21 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 21 sites in United States, China, Australia, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact MediLink Study Team (+86 0512-62858368, clinicaltrials@medilinkthera.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Nature and frequency of adverse events (AEs) with severity determined according to NCI CTCAE v5.0 (Part 1 and Part 4) (time frame: Approximately within 36 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.